Federal Court finds silodosin formulation patent valid but not infringed internationallawoffice.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from internationallawoffice.com Daily Mail and Mail on Sunday newspapers.
To print this article, all you need is to be registered or login on Mondaq.com.
On December 24, 2020, the Federal Court issued a decision in a
patent infringement action pursuant to s. 6(1) of the
Patented
Medicines (Notice of Compliance) Regulations relating to
silodosin (Allergan s
RAPAFLO):
Allergan Inc v Sandoz Canada
Inc, 2020 FC 1189. Chief Justice Crampton found
that Canadian Patent No. 2,507,002, relating to a capsule formulation
of silodosin, is not invalid on the basis of obviousness but not
infringed as the Sandoz Product does not contain granules and does not involve granulating or a wet granulation process , all of which were found to
To embed, copy and paste the code into your website or blog:
On December 24, 2020, the Federal Court issued a decision in a patent infringement action pursuant to s. 6(1) of the
Patented Medicines (Notice of Compliance) Regulations relating to
silodosin (Allergan’s
RAPAFLO):
Allergan Inc v Sandoz Canada Inc, 2020 FC 1189. Chief Justice Crampton found that Canadian Patent No. 2,507,002, relating to a capsule formulation of silodosin, is not invalid on the basis of obviousness but not infringed as “the Sandoz Product does not contain ‘granules’ and does not involve ‘granulating’ or a ‘wet granulation process’”, all of which were found to be essential elements.